Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is evaluated in four phase 1 clinical studies in patients with solid tumors or cutaneous T-cell lymphoma, acute myeloid leukemia, non-Hodgkin’s lymphoma, myelodysplastic syndrome and colorectal carcinoma across the US and the UK. The company partners with biotechnology and pharmaceutical companies. Forty Seven is headquartered in Menlo Park, California, the US.

Gain a 360-degree view of Forty Seven Inc and make more informed decisions for your business Gain a 360-degree view of Forty Seven Inc and make more informed decisions for your business Contact Us
Headquarters United States of America

Address 1490 Obrien Dr Ste A, Menlo Park, California, 94025-1499


Telephone 1 650 3524150

No of Employees 68

Industry Pharmaceuticals and Healthcare

Revenue (2019) $15.7M

   

   

Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

Forty Seven Inc premium industry data and analytics

15+

Catalyst Calendar

Proactively evaluate Forty Seven Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

9

Clinical Trials

Determine Forty Seven Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

4

Pipeline Drugs

Identify which of Forty Seven Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

4

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products
Pipeline
5F9 for the treatment of solid tumors and AML MDS
5F9 + Rituximab for the treatment of B-Cell NHL
XYZ
XYZ
XYZ
Understand Forty Seven Inc portfolio and identify potential areas for collaboration Understand Forty Seven Inc portfolio and identify potential areas for collaboration Contact Us
Image for loader

Competitor Comparison

Key Parameters Forty Seven Inc Legend Biotech Corp Ambrx Biopharma Inc Aileron Therapeutics Inc Exo Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Menlo Park Somerset La Jolla Waltham Watertown
State/Province California New Jersey California Massachusetts Massachusetts
No. of Employees 68 1,390 66 6 -
Entity Type Private Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Executives
Name Position Board Since Age
Mark McCamish Director; President; Chief Executive Officer Executive Board 2017 67
Ann D Rhoads Chief Financial Officer Senior Management - -
Chris H Takimoto Chief Medical Officer Senior Management - -
Jens-Peter Volkmer Vice President - Research and Early Development Senior Management - -
Mark Chao Vice President - Clinical Development Senior Management - -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Forty Seven Inc key executives to enhance your sales strategy Gain insight into Forty Seven Inc key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward